This past trading week (January 2-5) had a day less of trading, still, the cannabis market was rocked on Thursday after a report on U.S. Attorney General Jeff Sessions pointed to a change in policy creating uncertainty in the market. A response from this report and market news complete this week’s Cannabis Weekly Round-Up.

Attorney General goes against cannabis, causes severe decline in the market

The uncertainty of the cannabis market grew this past week as U.S. Attorney General Jeff Sessions sent marijuana stocks into a day of public losses after a report from the AP, indicated he would be rescinding Obama era policy letting states regulate cannabis without federal interference. This distinction of government powers is crucial, as several states have legalized marijuana, however on a federal level the drug is still illegal.
This week the Investing News Network (INN) reported on the memorandum from Sessions rescinding the Cole Memo, policy from the Obama administration protecting states where cannabis is legal from federal enforcement and its effect on the public market for cannabis investors.

US Election 2020 and Cannabis

 
Investing in cannabis? Read what experts have to say about cannabis and the US Election!
 

Companies respond to the Sessions memo

The wide-ranging effect of this decline was so severe several cannabis players made statements to express their response to the report of the Attorney General. While a group of major Licensed Producers (LPs) like Canopy Growth (TSX:WEED) and MedRelead (TSX:LEAF) reassured shareholders their business had no connection to the interests below the border, other more involved companies had to respond more directly.
“It is our belief that this Memorandum has more to do with the DOJ’s desire to ensure its ability to continue to enforce federal law without specific enforcement priorities regarding cannabis, than it does to disrupting ongoing state-legal cannabis activity,” Marc Lusting, CEO of CannaRoyalty (CSE:CRZ; OTCQX:CNNRF) said in a statement. “While the release of the Memorandum may mean some volatility for U.S. players over the short-term, we see significant opportunity for growth over the coming year and will continue to work to drive value for our shareholders.”
Another operator with significant interest in the U.S. market is Liberty Health Sciences (CSE:LHS; OTCQX:LHSIF), in their statement to shareholders, the company said it was entirely focused on the medical cannabis market, not the recreational one, which in their eyes was one of the driving forces behind the new Sessions policy. The company cited other legislative protections for their business and stated figures on the support for the legalization of cannabis.
“It is our interpretation that the memorandum… is largely in response to the recreational cannabis marketplace in California becoming effective on January 1, 2018. It does not affect the medical cannabis marketplace,” Liberty Health Sciences wrote.


Bruce Linton, CEO of Canopy told shareholders in a statement the management team of his company see the “confusion” in the U.S. market as an advantage for the company.
iAnthus Capital Holdings (CSE:IAN; OTCQB:ITHUF), another U.S. focused operator offered to investors, who may be nervous after yesterday’s decline that president Trump has voiced support for cannabis in the past. However, on Thursday (January 4) Press Secretary Sarah Huckabee Sanders told reporters, Trump “believes in enforcing federal law… whether it’s marijuana or whether it’s immigration.”
“There is no new policy that directs or demands the U.S. Attorneys to prosecute individuals in states where marijuana programs are legal. U.S. Attorneys will continue to have the same wide prosecutorial discretion that they had prior to today,” the company said.

Market News

Newstrike Resources’ (TSXV:HIP) stock rose on Friday after it received a license amendment from Health Canada for its subsidiary Up Cannabis. The change will now allow the producer to sell cannabis in dried marijuana form.
“We have been confident throughout our process that we would receive the regulatory approvals we require to access the exciting opportunities that Canada’s adult-use cannabis market will present,” Jay Wilgar, CEO of Newstrike and Up Cannabis said in a statement to investors. “With this approval in hand, we have all of the key strategic elements in place to move forward successfully.”
Thanks to the Friday announcement Newstrike’s stock had 38.89 percent boost. This past week Newstrike has increased its share price 66.13 percent.


During this trading week, the Australian government declared its intentions to become the “world’s leading exporter of medicinal cannabis” according to a report from the BBC.
The plan from the Australian administration is to change national regulations and join countries like Canada with the policy allowing the sale of products besides from the national market.
“Our goal is very clear: to give Australian farmers and manufacturers the best shot at being the world’s number one exporter of medicinal cannabis,” Health Minister Greg Hunt told the BBC.
INN offered investors with a recap of the battle between CanniMed Therapeutics (TSX:CMED) and Aurora Cannabis (TSX:ACB), as the latter tries to acquire its fellow LP. The aggressive strategy from Aurora was aggravated by CanniMed’s intention to conduct a poison pill business move by acquiring Newstrike Resources. After regulators got involved the situation is on hold until all the parties hold shareholder meetings.
However, this past week CanniMed announced a partnership with Newstrike outside of the proposed acquisition, a deal that Aurora has called into question in a public statement. Cam Battley, Executive Vice President of Aurora said if CanniMed needed to buy cannabis from another producer, “they could easily have signed a supply agreement with any number of producers currently licensed to sell.”
Aurora demanded to know the exact terms of the deal and confidently stated if its acquisition of CanniMed goes through it would review this transaction.
After suffering the decline from Thursday, the Marijuana Life Sciences Index ETF (TSX:HMMJ) recovered on Friday, seeing a 3.85 percent increase in value, while over the trading week the ETF had a 39.97 percent rise. As of 1:09 p.m. EST on Friday, the ETF traded at $22.11. Since its inception earlier this year, the index has gone up 115.9 percent.
Don’t forget to follow us @INN_LifeScience and @INN_Cannabis for real-time news updates!
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

US Election 2020 and Cannabis

 
Investing in cannabis? Read what experts have to say about cannabis and the US Election!
 

** This article is updated each week. Please scroll to the top for the most recent information**

Cannabis Weekly Round-Up: Manitoba Set to Pick 4 Retail Leaders for Recreational Business

By Bryan Mc Govern – Dec. 31, 2017
With Christmas and Boxing Day in Canada, this past trading week (Dec. 26-29) saw a reduction of trading days. However, there were still some developments to look over in the Investing News Network’s (INN) cannabis weekly round-up.
The race for retail space in Manitoba is gaining steam, as the province announced it would pick four marijuana retail proposals from, according to the Canadian Press over 100 applications now. The applicants that earn one of the coveted spots will be made aware in February, said Blaine Pedersen, Manitoba’s minister of growth, enterprise, and trade.
The report singled Delta 9 (TSXV:NINE) as one of the public applicants for the option to sell recreational cannabis-based products. The company brings to the table a Licensed Producer (LP) status on a federal level and a partnership with Canopy Growth (TSX:WEED) for its claim. John Arbuthnot, CEO of Delta 9, said obtaining one of the four retail licenses in Manitoba could lead to operating dozens of retail locations.
Amid no apparent news or transactions Canopy’s (TSX:WEED) stock saw a 20.11 percent increase on Wednesday (Dec. 27) and continued into Thursday (Dec. 28), closing that day up an extra 9.51 percent. Paul Taylor, chief investment officer of asset allocation at BMO Global Asset Management told Business News Network on Thursday this kind of market movement is something that couldn’t be ignored anymore.
“If you’re a Canadian equity manager running a serious portfolio you now have to have a view,” Taylor said. This recognition serves as another reminder of the maturity the cannabis industry is starting to reach.

US Election 2020 and Cannabis

 
Investing in cannabis? Read what experts have to say about cannabis and the US Election!
 

Company News

As the business of marijuana continues to expand into novel areas, the medical side hasn’t stayed behind and this past week GW Pharmaceuticals plc (NASDAQ:GWPH) announced the US Food and Drug Administration (FDA) has approved their Priority Review application for their NDA candidate Epidiolex. This candidate is based in the company’s lead cannabidiol (CBD) product treating seizures associated with Lennox-Gastaut syndrome (LGS) and Dravet syndrome.
“We look forward to working with the FDA during the review process to support the case for approval of Epidiolex,” Justin Gover, CEO of GW said. The company expects the FDA to complete its review by next June.
Despite fewer days of trading, the Canadian marijuana ETF still managed to get some growth this past trading week. Over the three-day trading period, the Marijuana Life Sciences Index ETF (TSX:HMMJ) enjoyed a 15.31 percent increase. As of 1:18 p.m. EST on Friday, the ETF traded at $18.23. Since its inception earlier this year, the index has gone up 77.85 percent.
Don’t forget to follow us @INN_LifeScience and @INN_Cannabis for real-time news updates!
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

  • Company surpassed 5,600 patient prescriptions for its medical cannabis products in Colombia . Prescriptions filled increased over 450% in Q3 2020 over Q2 2020
  • Khiron declared a National Strategic Project by the Government of Colombia , simplifying and accelerating administration and processes for the Company in executing strategic projects in Colombia and for export
  • Subsequent to the quarter, the Company completed a bought deal financing on November 26, 2020 , selling 32,200,000 units at a price of $0.45 per unit for aggregate gross proceeds of $14,490,000 CAD
  • Khiron signed partnerships with 15 clinics and health centres in Colombia , extending education and sales reach further across the country
  • As a result of the Company’s Doctor Zerenia TM telehealth platform more than 25% of the Company’s medical cannabis prescriptions came from outside of Bogota , expanding geographic presence of its Colombian clinics
  • Company achieved first sales of High CBD medical cannabis through private pharmacies in Peru . Additional approval received from Peru’s drug regulatory authority for Company’s High THC cannabis, with first prescriptions anticipated in Q1 2021
  • Expanded medical cannabis E-Learning platform to UK market in partnership with Medical Cannabis Clinicians Society (“MCCS”)
  • Entered an exclusive partnership with Rappi SAS, Latin America’s largest home multi-vertical app platform to distribute the Company’s CPG product portfolio, introducing Kuida products to Rappi users across the LatAm region
  • Signed agreement to distribute the Company’s Kuida TM CBD skincare brand through pharmacy, beauty retail and online markets serving the Hong Kong territory, with first orders expected in Q4 2020
  • Prudent cash use of $5 million in Q3 2020, compared with $4 million in Q2 2020, $12 million in Q1 2020 and $10 million in Q4 2019

 Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV: KHRN ), (OTCQX: KHRNF), ( Frankfurt : A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe announced today its financial results for the quarter ended September 30, 2020 . These filings are available for review on the Company’s SEDAR profile at www.sedar.com All financial information in this press release is reported in Canadian dollars, unless otherwise indicated.

Keep reading... Show less
  • Q3 Systemwide Pro Forma Revenue increased 18% quarter-over-quarter to $22.3 million , 170% year-over-year – Company became cash flow positive from operations in August
  • Company sale leaseback transaction with Innovative Industrial Properties scheduled to close within two weeks. As a result of close, together with proceeds from the recently closed bought deal financing, the Company will have $16 million of cash and $43 million in long-term debt
  • Company is in the process of acquiring acreage to construct up to 210,000 square feet of flowering canopy and supporting manufacturing facility in Cook County, Illinois to exponentially increase capacity in state
  • Initial guidance for 2021 with Systemwide Pro Forma Revenue of $170 -180 million and Adjusted EBITDA of $40 -50 million
  • The Company’s existing projects at maturity represent a long-term revenue and EBITDA opportunity upwards of $650 million and $250 million

4Front Ventures Corp. (CSE: FFNT) (OTCQX: FFNTF) (” 4Front ” or the ” Company “) today announced its financial results for the third quarter of 2020. All financial information is presented in U.S. dollars unless otherwise indicated.

Third Quarter 2020 Financial Results Highlights

Keep reading... Show less
  • Q3 Systemwide Pro Forma Revenue increased 18% quarter-over-quarter to $22.3 million , 170% year-over-year – Company became cash flow positive from operations in August
  • Company sale leaseback transaction with Innovative Industrial Properties scheduled to close within two weeks. As a result of close, together with proceeds from the recently closed bought deal financing, the Company will have $16 million of cash and $43 million in long-term debt
  • Company is in the process of acquiring acreage to construct up to 210,000 square feet of flowering canopy and supporting manufacturing facility in Cook County, Illinois to exponentially increase capacity in state
  • Initial guidance for 2021 with Systemwide Pro Forma Revenue of $170 -180 million and Adjusted EBITDA of $40 -50 million
  • The Company’s existing projects at maturity represent a long-term revenue and EBITDA opportunity upwards of $650 million and $250 million

4Front Ventures Corp. (CSE: FFNT) (OTCQX: FFNTF) (” 4Front ” or the ” Company “) today announced its financial results for the third quarter of 2020. All financial information is presented in U.S. dollars unless otherwise indicated.

Third Quarter 2020 Financial Results Highlights

Keep reading... Show less

Shareholders with losses exceeding $50,000 are encouraged to contact the firm

The Law Offices of Frank R. Cruz reminds investors of the upcoming December 1, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Aurora Cannabis, Inc. (“Aurora” or the “Company”) (NYSE: ACB ) securities between February 13, 2020 and September 4, 2020 , inclusive (the “Class Period”).

Keep reading... Show less

Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company”) is pleased to announce the launch of preclinical research studies using psilocybin and N-Acetylcysteine (“NAC”) for the treatment of mild traumatic brain injuryconcussion (“mTBI”) with post-traumatic stress disorder (“PTSD”). The study is in collaboration with a multidisciplinary team of scientists and physicians at the University of Miami Miller School of Medicine under the lead of Michael E. Hoffer, M.D., professor of otolaryngology and neurological surgery.

NAC has been shown to be safe and efficacious in a phase I human clinical study in treating military personnel who had suffered mTBI. The initial research focus is to demonstrate the safety and efficacy of the combination of psilocybin and NAC using broadly accepted rodent models. Final results are expected in 2021. Once this is established, more specific work can examine dose response, medicine uptake, and medicine levels. The research team at the Miller School of Medicine has conducted prior studies involving NAC with mTBI and has a license from the United States Drug Enforcement Administration to conduct research using Schedule I controlled substances, which includes psilocybin.

Keep reading... Show less